Acamprosate Calcium 333 mg Tablets
Mylan recalls Acamprosate Calcium 333 mg tablets over dissolution failure.
Consumers who have the affected product should stop using it and contact their pharmacist or healthcare provider for a replacement or guidance. Return the product to the place of purchase if instructed.
Why it was recalled
Mylan Pharmaceuticals is recalling Acamprosate Calcium Delayed-Release Tablets, 333 mg, 180-count bottles, because they failed dissolution specifications, which may affect drug performance.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Acamprosate Calcium, Delayed-Release Tablets
- Lot code
- 3227809
- Strength
- 333 mg
- NDC / UPC
- NDC 0378-6333-80
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other Dissolution Failure recalls
Other recent recalls from MYLAN PHARMACEUTICALS INC
Editorial summary by Recall Canary · summary updated 2026-08-21 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification